Table 3.
Summary of antibody characterization
| isotype | Minimal linear epitope | Ab sequences | Protection against VACVb | |||
|---|---|---|---|---|---|---|
|
| ||||||
| HC | LC | |||||
| Mouse #1 | AD5 | 2b | ||||
| AD10 | 3 | |||||
| BF8 | 1 | − | ||||
| FE11 | 2b | A | ||||
| GH3 | 3 | |||||
| JG8 | 3 | |||||
| JE1 | 3 | a | ||||
| LB8 | 3 | 76-88 | ||||
| CE11 | 3 | |||||
| DF8 | 3 | |||||
| KD8 | 3 | B | ||||
| LE11 | 3 | |||||
| TH6 | 3 | |||||
| BF9 | 2b | C | c | |||
| HE6 | 2b | ++ | ||||
| BB5 | 3 | D | d | |||
| 3G6 | 2b | |||||
| 4C5 | 3 | 76-90 | E | e | ||
| Mouse #2 | 12G9 | 3 | ||||
| 12B4 | 3 | F | d | |||
| 9C3 | 2a | 71-90 | G | g | ++ | |
| 8C6 | 2a | ~12-64 | H | e | + | |
++, similar to positive control (anti-H3 #41); −, similar to negative control (anti-A10, BG3); +, intermediate between positive and negative